Loading…
Underlying
Underlying Price
$8.36
Type
Call
Strike
8.5
Expiration
Oct 30, 2026
DTE
10d
Moneyness
OTM
Intrinsic
$0.00
IBRX 8.5 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | $1.82 | -4.71% | 11 | 223 |
| Oct 30, 2026 | 10d | $1.48 | +11.28% | 7 | 115 |
| Nov 6, 2026 | 17d | $2.20 | +37.50% | 4 | 20 |
| Nov 13, 2026 | 24d | — | — | 0 | 0 |
| Nov 27, 2026 | 38d | — | — | 0 | 0 |
IBRX Nearby Strikes · Oct 30, 2026
| Strike | Last | Change | Vol | Open Int | Moneyness |
|---|---|---|---|---|---|
| 5.5 C | $3.03 | -9.01% | 1 | 1 | ITM |
| 6 C | — | — | 0 | 0 | ITM |
| 6.5 C | — | — | 0 | 0 | ITM |
| 7 C | $3.76 | +34.29% | 7 | 11 | ITM |
| 7.5 C | $2.75 | -17.91% | 4 | 98 | ITM |
| 8 C | $1.42 | -29.00% | 8 | 45 | ITM |
| 8.5 C | $1.48 | +11.28% | 7 | 115 | OTM |
| 9 C | $0.74 | -50.67% | 437 | 1,453 | OTM |
| 9.5 C | $1.24 | +1.64% | 8 | 239 | OTM |
| 10 C | $0.32 | -54.29% | 35 | 953 | OTM |
| 10.5 C | $0.22 | -60.00% | 64 | 472 | OTM |
| 11 C | $0.25 | -28.57% | 23 | 1,984 | OTM |
| 11.5 C | $0.10 | -82.14% | 72 | 769 | OTM |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.